A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Erica S TsangRahul R AggarwalMallika S DhawanEmily K BergslandEdwin A AlvarezSusan CalabreseRomain PacaudJose GarciaDelaire FattahScott ThomasJennifer GrabowskyMark M MoasserPamela N MunsterPublished in: Cancer research communications (2022)
The PI3K inhibitor alpelisib has limited activity alone, but there is interest in combinations in platinum-resistant tumors. In this phase Ib study of alpelisib with cisplatin, the objective response rate measured 29% but adverse events limited dose intensity. These promising results provide rationale for studying combinations with better tolerated platinum agents.